ProCE Banner Activity

Answering the Questions on Choosing Between Initial ART Options

Video

Drs Marta Boffito and Michelle Cespedes discuss questions about first-line antiretroviral therapy, from Clinical Care Options (CCO).

Released: May 30, 2023

Share

Faculty

Marta Boffito

Marta Boffito, MD, PhD, FRCP, MBA

Consultant Physician
Clinical Director
HIV, Sexual and Gender Health, Dermatology
Chelsea and Westminster Hospital NHS Foundation Trust
Imperial College London
London, United Kingdom

Michelle Cespedes

Michelle Cespedes, MD, MS

Professor of Medicine
Division of Infectious Disease
Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc. and ViiV Healthcare.

Gilead Sciences, Inc.

ViiV Healthcare

Disclosure

Primary Author

Marta Boffito, MD, PhD, FRCP, MBA

Consultant Physician
Clinical Director
HIV, Sexual and Gender Health, Dermatology
Chelsea and Westminster Hospital NHS Foundation Trust
Imperial College London
London, United Kingdom

Marta Boffito, MD, PHD, FRCP: consultant/advisor/speaker: AstraZeneca, Atea, Gilead, Merck Sharp and Dohme, Pfizer, Roche, ViiV.

Michelle Cespedes, MD, MS

Professor of Medicine
Division of Infectious Disease
Department of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Michelle Cespedes, MD, MS: consultant/advisor/speaker: Gilead, ViiV.